Published in Pharmacol Ther on April 02, 2011
Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol (2014) 0.98
Monoamine oxidases as sources of oxidants in the heart. J Mol Cell Cardiol (2014) 0.94
Microarray analyses to quantify advantages of 2D and 3D hydrogel culture systems in maintaining the native valvular interstitial cell phenotype. Biomaterials (2015) 0.93
Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity. ACS Med Chem Lett (2011) 0.86
Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology (2013) 0.86
Directing valvular interstitial cell myofibroblast-like differentiation in a hybrid hydrogel platform. Adv Healthc Mater (2014) 0.84
Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys. J Pharmacol Exp Ther (2015) 0.83
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol Psychiatry (2016) 0.83
Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. Pharmacol Res Perspect (2014) 0.82
Mechanisms of calcification in aortic valve disease: role of mechanokinetics and mechanodynamics. Curr Cardiol Rep (2013) 0.79
Serotonin paracrine signaling in tissue fibrosis. Biochim Biophys Acta (2012) 0.79
Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience (2016) 0.78
(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology (Berl) (2014) 0.77
Creation of a free, Internet-accessible database: the Multiple Target Ligand Database. J Cheminform (2015) 0.75
Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer (2014) 0.75
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophr Res Treatment (2016) 0.75
Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro. Cardiovasc Pathol (2016) 0.75
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med (2008) 10.03
Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med (1997) 9.36
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31
Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature (1952) 6.91
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
A review of central 5-HT receptors and their function. Neuropharmacology (1999) 6.13
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med (2007) 5.95
Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol (2007) 5.60
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med (2005) 4.93
Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation (1994) 4.32
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med (1966) 3.80
Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science (1991) 3.73
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation (2001) 3.47
Drugs and valvular heart disease. N Engl J Med (2007) 3.41
TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res (2004) 3.20
The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. Br J Pharmacol Chemother (1959) 3.17
Valvular heart disease in patients taking pergolide. Mayo Clin Proc (2002) 3.00
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation (2002) 2.93
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation (2006) 2.68
Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol (1996) 2.60
Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res (2004) 2.45
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 2.41
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther (1994) 2.27
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation (2001) 2.17
Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis (2004) 2.02
Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther (2002) 1.99
G-protein-coupled receptors at a glance. J Cell Sci (2003) 1.92
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res (2008) 1.87
Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol (2006) 1.83
Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res (1985) 1.81
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res (2005) 1.80
Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol (2001) 1.78
Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A (2000) 1.75
Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis. Am J Physiol Heart Circ Physiol (2005) 1.73
Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett (1995) 1.73
Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol (2001) 1.72
Hypercholesterolemic aortic-valve disease. N Engl J Med (2003) 1.71
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol (2000) 1.64
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.61
Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation (2002) 1.61
Biaixal stress-stretch behavior of the mitral valve anterior leaflet at physiologic strain rates. Ann Biomed Eng (2006) 1.60
Mining the receptorome. J Biol Chem (2004) 1.58
Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci (1967) 1.55
Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem (2002) 1.54
5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther (2006) 1.53
The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med (1998) 1.51
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol (2003) 1.47
Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol (1994) 1.46
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Eur J Echocardiogr (2010) 1.43
Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol (2009) 1.42
Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol (2007) 1.41
An ex vivo study of the biological properties of porcine aortic valves in response to circumferential cyclic stretch. Ann Biomed Eng (2006) 1.34
The effects of cellular contraction on aortic valve leaflet flexural stiffness. J Biomech (2005) 1.33
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf (2010) 1.32
Long-term serotonin administration induces heart valve disease in rats. Circulation (2005) 1.32
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther (1998) 1.31
Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol (2002) 1.30
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol (2007) 1.29
Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am J Pathol (2010) 1.29
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Molecular and functional characteristics of heart-valve interstitial cells. Philos Trans R Soc Lond B Biol Sci (2007) 1.27
Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem (2008) 1.20
Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci (2008) 1.20
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Development and progression of aortic valve stenosis: atherosclerosis risk factors--a causal relationship? A clinical morphologic study. Clin Cardiol (1991) 1.17
Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum (2008) 1.16
Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol (2009) 1.16
5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A (2000) 1.15
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther (2002) 1.14
Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling. J Heart Valve Dis (2002) 1.13
Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol (2009) 1.12
TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol (2008) 1.12
Serotonin receptors - from molecular biology to clinical applications. Physiol Res (2010) 1.12
Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol (2005) 1.12
Differences in tissue-remodeling potential of aortic and pulmonary heart valve interstitial cells. Tissue Eng (2007) 1.11
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther (2001) 1.11
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol (1994) 1.10
Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem (1996) 1.09
TGF-beta-regulated collagen type I accumulation: role of Src-based signals. Am J Physiol Cell Physiol (2006) 1.06
Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation (2001) 1.05
Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology (1995) 1.04
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol (2002) 1.04
Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology (1984) 1.03
A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med (1984) 1.03
Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol (2007) 1.03
Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation (2003) 1.01
Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett (1996) 1.00
The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. J Biol Chem (2002) 1.00
5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol (2008) 0.98
Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol (1994) 0.97
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J (2008) 0.97
Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) (2008) 0.96
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A (2007) 7.96
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest (2011) 5.12
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron (2009) 4.98
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Generation of a synthetic memory trace. Science (2012) 3.55
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci (2010) 3.55
The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (2004) 3.54
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Remote control of neuronal signaling. Pharmacol Rev (2011) 2.66
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
In-vivo dynamic deformation of the mitral valve anterior leaflet. Ann Thorac Surg (2006) 2.28
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron (2013) 2.01
DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol (2014) 1.99
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther (2004) 1.97
Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov (2005) 1.93
Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci (2014) 1.92
G-protein-coupled receptors at a glance. J Cell Sci (2003) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res (2008) 1.87
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem (2005) 1.78
In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther (2003) 1.70
A pharmacological organization of G protein-coupled receptors. Nat Methods (2013) 1.65
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett (2004) 1.65
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.61
Mining the receptorome. J Biol Chem (2004) 1.58
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol (2008) 1.57
Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem (2002) 1.54
In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol (2013) 1.47
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol (2003) 1.47
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci (2009) 1.46
Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol Dis (2010) 1.46
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
An elastic, biodegradable cardiac patch induces contractile smooth muscle and improves cardiac remodeling and function in subacute myocardial infarction. J Am Coll Cardiol (2007) 1.44
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol (2009) 1.44
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci (2003) 1.42
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci (2010) 1.38
Engineered GPCRs as tools to modulate signal transduction. Physiology (Bethesda) (2008) 1.37
Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol (2011) 1.37
Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem (2004) 1.37
Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A (2012) 1.36
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther (2005) 1.29
A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem (2003) 1.28
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Massively parallel screening of the receptorome. Comb Chem High Throughput Screen (2008) 1.27
Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem (2002) 1.27
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc (2010) 1.26
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A (2009) 1.26
Thy-1-integrin alphav beta5 interactions inhibit lung fibroblast contraction-induced latent transforming growth factor-beta1 activation and myofibroblast differentiation. J Biol Chem (2010) 1.25
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev (2004) 1.24
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem (2013) 1.23
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology (2008) 1.21
Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci (2008) 1.20
Salvinorin A: from natural product to human therapeutics. Mol Interv (2006) 1.19
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. J Med Chem (2012) 1.19
Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology (2006) 1.18
A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology (2012) 1.17
Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2). J Biol Chem (2009) 1.16
Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett (2007) 1.16
Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci (2007) 1.16
Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther (2006) 1.15
Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol (2012) 1.15
Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Neuropharmacology (2010) 1.15
Caveolin-1 and lipid microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase signaling. Mol Pharmacol (2009) 1.15
Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors. Biochemistry (2005) 1.13
Colloidal aggregation causes inhibition of G protein-coupled receptors. J Med Chem (2013) 1.13
Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol (2005) 1.12
L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J Pharmacol Exp Ther (2003) 1.10
Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry (2009) 1.10